Stockbabie NewsFatherMarketNewsMarket Intelligence
MARKETS
Wire · Earnings
Earnings

Boston Scientific Lowers FY2026 Adj EPS Guidance from $3.28-$3.32 to $3.16-$3.18 vs $3.23 Est; Lowers FY2026 Sales Guidance from $21.178B-$21.379B to $20.927B vs $21.143B Est

Oct 28, 2026 · 06:33 AM ET· updated 1h ago

Boston Scientific (NYSE:BSX) lowers FY2026 Adj EPS guidance from $3.28-$3.32 to $3.16-$3.18 vs $3.23 analyst estimate. Lowers FY2026 sales outlook from $21.178 billion-$21.379 billion to $20.927 billion vs $21.143

Share
Why It Matters

Boston Scientific told investors it will make less money next year than it said before. When a company lowers its targets, pay attention to whether things get better later or stay weaker.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
BSX42.49
-2.57 (-5.70%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.